Mar. 31 at 12:57 AM
$VLVLY $SHOT $LLY $NVO $WHTCF
TOP 5 WEEKEND STORIES:
1) The Board of Directors of Volvo Cars (VLVLY) has appointed Hakan Samuelsson as Chief Executive Officer and President. Hakan will serve a two-year term, starting April 1, 2025. This ensures stability while preparing to appoint a long-term successor. Hakan Samuelsson served on the Volvo Cars Board from 2010 and as CEO from 2012 to 2022. During his leadership, Volvo Cars was successfully repositioned as a global premium automotive brand and publicly listed. Subsequently, he served as Chairperson of Polestar until 2024.
2) Safety Shot (SHOT) announced that the record date for the spin-off and distribution of shares of common stock, par value
$0.0001 per share, of Caring Brands, currently a subsidiary of the Company, has been set for April 7, 2025. Stockholders of the Company and holders of certain warrants issued in the Company's public offering in July 2021 will receive one share of Caring Brands Common Stock, for every 45 shares of the Company's common stock held or underlying the Warrants as of the Record Date.
3) Novo Nordisk (NVO) presented results from STRIDE, its phase 3b trial investigating the effects of once-weekly Ozempic injection 1 mg in adults with type 2 diabetes and early-stage symptomatic PAD1, at the American College of Cardiology's, ACC, Annual Scientific Session and Expo. The results were presented during a late-breaking clinical trial session and highlighted at an official ACC press conference. In addition, the analysis was also simultaneously published today in The Lancet. The double-blind, randomized, placebo-controlled STRIDE trial, which enrolled 792 adults with type 2 diabetes and symptomatic PAD, achieved its primary endpoint, with semaglutide 1 mg demonstrating a 13% superior improvement in maximum walking distance and a clinically meaningful median treatment difference of 26.4 meters on a 12% incline, compared to placebo at 52 weeks.
4) Eli Lilly and Company (LLY) announced positive Phase 2 results for lepodisiran, an investigational small interfering RNA, siRNA, therapy designed to lower the production of lipoprotein, a genetically inherited risk factor for heart disease. In the Phase 2 ALPACA study, lepodisiran significantly reduced Lpa levels by an average of 93.9% over the 60 to 180-day period after treatment with the highest tested dose, meeting the primary endpoint.
5) WELL Health Technologies (WHTCF) announces that it will be delaying the filing of its audited annual consolidated financial statements for the year ended December 31, 2024, the related management's discussion and analysis, and related CEO and CFO certificates beyond the March 31, 2025 deadline. The delay is resulting from the accounting implications related to the Company's non-wholly owned Delaware subsidiary Circle Medical Technologies.
